FDA Drug Shortage Database
Lorazepam (Ativan) shortage
The FDA Drug Shortage Database lists 10 of 11 lorazepam presentations as limited or unavailable (updated October 5, 2026); the first entry was posted on May 3, 2018. 1 more presentation is on the list as available.
- Generic listed
- In shortage
- Boxed warning
- DEA Schedule IV
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 2mg/1ml injection | 6 | 1 | 0 |
| 4mg/1ml injection | 4 | 0 | 0 |
Which presentations are listed?
Limited or unavailable now (10)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Unavailable; Other |
| Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Limited Availability; Demand increase for the drug |
| Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Unavailable; Other |
| Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Unavailable; Other |
| Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Limited Availability; Demand increase for the drug |
| Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Unavailable; Other |
| Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02) | Fresenius Kabi USA, LLC | Current posted May 3, 2018, updated September 15, 2026 | Unavailable; Demand increase for the drug |
| Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30) | Hospira, Inc., a Pfizer Company | Current posted May 3, 2018, updated September 22, 2026 | Limited Availability; Demand increase for the drug |
| Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25) | Hikma Pharmaceuticals USA, Inc. | Current posted September 5, 2018, updated September 18, 2026 | Unavailable; Other |
| Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10) | Hikma Pharmaceuticals USA, Inc. | Current posted May 3, 2018, updated September 18, 2026 | Unavailable; Other |
Listed now, available (1)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) | Amphastar Pharmaceuticals, Inc. | Current posted May 3, 2018, updated October 5, 2026 | Available |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Clonazepam | Anxiety | In shortage | 31 labelers | $0.0244 per tablet 1 mg tablet |
| Alprazolam | Anxiety | No current entry | 30 labelers | $0.0236 per tablet 0.25 mg tablet |
| Diazepam | Anxiety | No current entry | 45 labelers | $0.0283 per tablet 10 mg tablet |
| Chlordiazepoxide | Anxiety | No current entry | 15 labelers | $0.158 per capsule 25 mg capsule |
| Clorazepate | Anxiety | No current entry | 8 labelers | $0.524 per tablet 3.75 mg tablet |
| Oxazepam | Anxiety | No current entry | 6 labelers | $0.725 per capsule 10 mg capsule |
| Amitriptyline and chlordiazepoxide | Anxiety | No current entry | 1 labeler | $1.20 per unit 5-12.5 |
| Buspirone | Anxiety | No current entry | 47 labelers | $0.043 per tablet 15 mg tablet |
| Hydroxyzine | Anxiety | No current entry | 61 labelers | $0.0326 per tablet 25 mg tablet |
| Meprobamate | Anxiety | No current entry | 3 labelers | $5.89 per tablet 400 mg tablet |
| Amitriptyline and perphenazine | Anxiety | No current entry | 1 labeler | n/a |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage